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Abstract
Background: Natural killer (NK) cells comprise the main components of lymphocyte-mediated nonspecific
immunity. Through their effector function they play a crucial role combating bacterial and viral challenges.
They are also thought to be key contributors to the systemic spinal cord injury-induced immune-deficiency
syndrome (SCI-IDS). SCI-IDS increases susceptibility to infection and extends to the post-acute and
chronic phases after SCI.
Methods and design: The prospective study of NK cell function after traumatic SCI was carried out in
two centers in Berlin, Germany. SCI patients and control patients with neurologically silent vertebral
fracture also undergoing surgical stabilization were enrolled. Furthermore healthy controls were included
to provide reference data. The NK cell function was assessed at 7 (5–9) days, 14 days (11–28) days, and
10 (8–12) weeks post-trauma. Clinical documentation included the American Spinal Injury Association
(ASIA) impairment scale (AIS), neurological level of injury, infection status, concomitant injury, and
medications. The primary endpoint of the study is CD107a expression by NK cells (cytotoxicity marker)
8–12 weeks following SCI. Secondary endpoints are the NK cell’s TNF-α and IFN-γ production by the NK
cells 8–12 weeks following SCI.
Discussion: The protocol of this study was developed to investigate the hypotheses whether i) SCI
impairs NK cell function throughout the post-acute and sub-acute phases after SCI and ii) the degree of
impairment relates to lesion height and severity. A deeper understanding of the SCI-IDS is crucial to
enable strategies for prevention of infections, which are associated with poor neurological outcome and
elevated mortality.
Trial registration: DRKS00009855.
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Background
Infectious complications such as spinal cord injury (SCI)
- associated pneumonia (SCI-AP) are risk factors for
poor functional neurological recovery [1] and the leading
cause of morbidity and mortality among SCI patients
[2–4] during the post-acute and chronic phases after
injury. After SCI the normally well-balanced interplay
between the nervous system and immune system is
disrupted resulting in a systemic Spinal Cord Injury –
Induced Immunodefiency Syndrome (SCI-IDS) [5–7].
Downregulation of the immune system also occurs after
other central nervous system (CNS) injuries, such as
stroke and traumatic brain injury (TBI) [8, 9]. Immune
depression resulting from any of the previously men-
tioned conditions has previously been summarised using
the term CNS injury-induced immune depression syn-
drome (CIDS) [8–10].
Neural regulation of the immune system after SCI
occurs by at least three different pathways: 1) through a
neuroendocrine pathway – mainly the hypothalamic-
pituitary-adrenal (HPA) axis – that coordinates the
production and circulation of immunoregulatory hor-
mones and neurotransmitters such as glucocorticoids
[10–14]; 2) direct autonomic innervation through sym-
pathetic and parasympathetic nerves of endocrine,
hematopoietic and immune relevant organs such as
spleen, bone marrow, and lymph nodes [12, 14–16]. 3)
via cytokine synthesis at the sterile inflammatory CNS
injury site and/or systemically which may elicit a sys-
temic immune modulatory response through CNS-
specific mechanisms [17, 18].
SCI-IDS was first characterized in quantitative terms
[5, 6] as a reduction of leukocyte subpopulations such as
T-, and B-lymphocytes and MHC class II+ cells, oc-
curring during the first week after trauma as observed in
both experimental models and clinical pilot SCI studies [5,
6]. However, this transient lymphopenia alone cannot be
held accountable for the persistent increased susceptibility
to infectious diseases in SCI patients giving rise to the
possibility that a qualitative deficit might persist beyond
the first week after injury.
Due to NK cells’ highly heterogenic receptor repertoire
and long-lasting, specific memory [19], they belong to
the first line of defence directed against a varied
spectrum of intrudors including viral and bacterial anti-
gens [19–22]. NK cells are characterized by their high
cytotoxic potential, rapid activation and cytokine secre-
tion as well as their important modulatory role over
other immune competent cells, namely those related to
adaptive immunity, including macrocytic “priming” and
regulation of Th1/Th2 balance [22–25].
NK cells are equipped with beta-adrenergic [26] and
glucocorticoid-receptors [27] that orchestrate their activ-
ity. In physiological conditions, NK cell activity is
fostered after sport [28] and diminished after psycho-
logical stress in a beta-receptor-dependent manner.
Corticosteroids also attenuate NK cells activity after
iatrogenic surgical stress via activation of a stress/HPA
axis-mediated response [29].
Subsequent to SCI deficits in NK cell function at 2
weeks, a nadir at 2 months post-injury occurs, followed
by a sustained deficiency detectable up to more than a
year after SCI [30, 31]. Efferent sympathetic noradrener-
gic/peptidergic fibers are present in the parenchyma of
primary and secondary lymphoid organs including the
bone marrow where they travel along vasculature ending
in close proximity to precursor and hematopoietic cells
[12, 13, 15]. Based on this embedded and juxtaposed
neuroanatomical position it has been suggested that the
autonomic nervous system (ANS) exerts an immune
regulatory role. Bone marrow decentralization was
shown to have an adverse effect on lymphocyte prolifer-
ation, namely on long-term colony formation [31] pur-
portedly affecting NK cell formation and maturation in
the bone marrow [21]. As only mature NK cells are
able to elicit cell lysis, alterations with the matur-
ation process of NK cells might adversely interfere
with the development of their “killing machinery”
and functionality.
It remains unclear whether NK cell functional im-
pairment is caused by neurogenic-specific mechanisms.
In this prospective, longitudinal multicentre study, we
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analyse fluctuations of NK cells in peripheral blood
(quantitative aspect) together with remaining NK cell
functionality (qualitative aspect). Given that NK cell
function is crucial to combat viral and bacterial infec-
tions, and the ability to control infections after SCI [32]
is significantly impaired, we aim to investigate whether
lymphocyte mediated non-specific immunity driven by
NK cells is impaired after SCI and to characterize the
functional role of NK cells as a contributing factor to
the SCI-IDS. We propose to measure NK cell functional
parameters such as direct cytotoxicity and surrogate pa-
rameters thereof, including NK-cell activation and the
capacity to mount a characteristic cytokine expression
response, first, to scrutinize the degree of NK cell dys-
function induced by SCI and the one caused the post-
aggression syndrome (stress and surgery) [33] and sec-
ond to monitor the functional status of NK cells in the
search for prognostic markers in individuals at the high-
est risk of developing infections. Infections have been
shown to be an independent factor hindering wound
healing, including the spinal cord lesion itself thereby re-
ducing neurological recovery [1].
Driven by the lack of studies controlling for the effect
of stress-/trauma- and surgery-associated mechanisms
upon the NK cell function, our study aims to delineate
the degree of NK cell dysfunction not directly associated
with injury to the CNS by incorporating a group of
patients with acute vertebral facture without SCI. Add-
itionally, we analysed whether NK cell dysfunction is in-
fluenced by the disruption of the sympathetic outflow to
the immune-relevant organs (lesion level-dependency).
Furthermore, using FACS as a method, we are also able
not only to measure NK cells’ cytotoxicity but additional
crucial functional parameters such as cytokine produc-
tion, which have not been previously assayed.
Methods and design
Study design, study coordination, and participating
centers
This study was designed as a prospective two-center study
for the detailed evaluation of NK cell activity up to
10 weeks after SCI. The coordination of this study is con-
ducted by the Department of Experimental Neurology,
Clinical and Experimental Spinal Cord Injury Research
(Neuroparaplegiology) at the Campus Mitte of the Charité
University Hospital, Berlin, Germany. Patients were re-
cruited from two SCI specialized centres: the Treatment
Center for Spinal Cord Injuries, Trauma Hospital Berlin,
Germany and the Center for Musculoskeletal Surgery
(Charité - Campus Virchow Clinic).
Enrolment period
The recruitment and follow-up of patients started in
October 2012 and was closed in December 2014. Query
management, source-data verification and database clear-
ing was performed until March 2016. Statistical evaluation
and elaboration of a report are currently ongoing.
Ethics and informed consent
The study is associated with the SCIentinel study [34]
and its protocol was approved by the local Ethics
Committees: Ethical Committee of the Charité – Uni-
versitätsmedizin Berlin (EA1/001/09). Participants
were informed both in oral and written form about
the trial and its anticipated risks and benefits, using
patient information sheets. Written informed consent
was obtained prior to inclusion in the study. This
study complies with the Helsinki Declaration in its recent
German version, the Medical Association code of conduct,
the principles of Good Clinical Practice (GCP) and
the Federal Data Protection Act. The study is carried out
according to local legal and regulatory requirements. The
trial protocol was registered in the German clinical trials
registry (DRKS00009855).
Participants
A total of four groups were enrolled in the study. In
order to investigate whether the extent of NK cell
dysfunction is lesion level dependent, SCI patients were
separated in 2 groups i) patients with rostral lesions
(Th5 or above) and ii) patients with caudal lesions (Th6
or below), with a different degree of immune relevant
organ denervation and sympathetic outflow impairment.
Alterations in NK cell activity have been described not
only in cases of CNS disturbances [9, 13, 35] but also
after surgical procedures [29]. Therefore a control group
iii) including patients with an acute vertebral fracture,
undergoing stabilization surgery without SCI was enrolled
in order to distinguish neurogenic immune suppression
from stress (post-aggression-syndrome) associated altered
NK cell activity (Fig. 1). Reference values for the NK
cell function were given by an additional group (iv) of
healthy controls.
The estimated frequency of patients initially treated
with methylprednisolone in the recruiting centres is
expected to be between 5 and 10 %. These patients will
be excluded from the analysis of the primary endpoint
given the well-known suppressive effect of glucocorti-
coids on NK cells function [29].
Sample size calculation
The number of patients to be enrolled in this study was
calculated based on a previous study of Iversen and
colleagues (n = 18) analysing growth and activity of
leucocytes following SCI [31]. With regard to the com-
parison between 12 patients and 6 controls Iversen et al.
reported an effect size of around 1.6 (Cohen’s d) in
lymphocyte cytoxiticity (patients mean ± SEM,: 5.2 ± 0.7
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and 4.5 ± 0.7 g/L in the paraplegics and tetraplegics
patients with n = 6, respectively, versus 8.2 ± 0.8 g/L in
the control subjects, n = 6).
The primary endpoint in this study is the difference of
NK cell cytotoxicity (NK cell expression of CD107a)
during the sub-acute phase (assessed between 8 and 12
weeks after SCI) between all SCI patients and controls. The
sample size calculation (software R package ‘pwr’, https://
cran.r-project.org/web/packages/pwr/pwr.pdf) was per-
formed assuming an effect size of 1.0 for the difference
between all SCI patients (either with rostral lesions Th5 or
above, (group i) or with caudal lesions Th6 or below
(group ii) versus control patients with acute vertebral frac-
ture, but without SCI (group iii). Type I error was set
to 0.05 (two-sided); type II error to 0.2 (80 % Study
Power). To test the main hypothesis with a two sided t-
test, a total sample size of 36 SCI patients (pooled group i
and ii, n = 23) and controls (group iii, n = 13) would be
required. Aiming for adequate power for the testing of
secondary hypotheses between the two SCI patient groups
with different lesion levels and to account for possible
drop out we aimed to include at least 15–20 patients in
each of the three groups. Furthermore, we included a
small group of healthy controls (n = 10) as a reference
group (group iv).
Enrolment and eligibility criteria
After admission to the hospital, the patients were subject
to a clinical examination and an interview to establish
eligibility for the study. As this is a study associated with
the SCIentinel study [34] the selection criteria were
predefined accordingly and are in line with those of pre-
viously published studies [6, 36]. Study enrolment is in





















































Fig. 1 Numbers of study participants, groups and innervation of immune relevant organs. Recruited patients were allocated to 3 different
cohorts: i) patients with a SCI lesion at level Th5 and above (black); ii) patients with a SCI lesion at level Th6 and below (grey); iii) neurologically
silent patients with a vertebral fracture at any level. SCI-lesions at Th5 and above (i), depending on the completeness of the lesion (AIS A-D), result
in a partial or total denervation of the sympathetic pregranglionic neurons synapsing on the celiac ganglion and subsequent ganglia connected
to the segments below the lesion. In patients with lesions at Th6 and below (ii), the innervation of the celiac ganglion remains completely/partially
intact. In the third group the sympathetic innervation of neuroendocrine or primary and secondary immune organs remains intact (iii)
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admitted to this study must be 18 years or older with
acute isolated SCI after decompression or stabilization
surgery, or with a neurologically silent vertebral fracture
after stabilization surgery. Eligibility criteria were estab-
lished in order to minimize bias and to obtain represen-
tative data. Patients with extensive polytrauma or TBI
are to be excluded as these lesions may also have a detri-
mental effect on the immune system. Exclusion of pa-
tients with conditions that chronically induce changes
on the immune system such as clinical history of neopla-
sia, pre-existing infections, autoimmune disease or
chronic intake of corticosteroids limits the number of
possible confounding factors.
Documentation schedule
Study enrolment is documented in Case Report Forms
(CRFs). These include information about neurological
classification, injury date and time, medical history, con-
comitant injury, medication history, acute SCI therapy
concerning high-dose methylprednisolone treatment as
well as details of surgical intervention. Blood sampling
took place at 3 different time slots after the lesion as de-
scribed in the section “observational period” and was
scheduled between 7:00 and 11:00 a.m. to minimize the
influence of circadian rhythm on the tested parameters.
Neurological classification
Neurological evaluation was performed according to the
International Standards for Neurological Classification
of Spinal Cord Injury Patients (ISNCSCI) [37], a revision
of the American Spinal Injury Association (ASIA) classi-
fication in order to standardize the characterization of
the lesion by the collaborating centres. ISNCSCI com-
prises the assessment of completeness of lesion – ASIA
Impairment scale (AIS) – and the single neurological
level of the lesion.
Definition of infections
Another important clinical measure with crucial import-
ance for this study is the diagnosis of infectious diseases.
SCI-associated pneumonia and urinary tract infections
(UTIs) are the most prevalent infections within the SCI
population and are diagnosed and documented accord-
ing to published definition of disease to ensure compar-
ability [38, 39]. UTI is defined as bacteriuria greater
than 105 cells/ml or WBC count of more than 100/
mm3 - according to the National group on urologic re-
habilitation of paraplegics [38]. Pneumonia was diag-
nosed on the basis of the finding of opacities and
infiltrates in chest X-ray.
Target cell population
K562 is a human leukemic cell line devoid of MHC class I
and are therefore specific targets of NK cells [40]. They are
obtained from Deutsches Rheuma-Forschungszentrum
(DRFZ; courtesy of the Romagnani group) and kept under
sterile conditions in the Dept. of Experimental Neurology.
K562 are cultured in RPMI-1640 (Gibco) supplemented
with 10 % fetal calf serum (FCS) (lonza) and Penicillin
(100U/ml, Biochrom) Streptavidin (100 μg/ml, Biochrom).
The cell cultures are maintained at 37 °C, 5 % CO2.
Blood sample handling
Peripheral blood was drawn under sterile conditions
from each participant at the specified time points. All
samples are anonymized with a six-figure pseudonym
and any personal information of the participants is re-
moved. One 8 ml BD Vacutainer® CPT™/Ficoll™ tube was
collected from each admitted patient who fulfils the in-
clusion criteria for immediate preparation of peripheral
blood mononuclear cells (PBMCs).
NK cell stimulation assays [23–25, 40]
Before stimulation, the frequency of NK cells was calcu-
lated by flow cytometry (FACScalibur, BD biosciences)
and the effector:target cell ratio was established. In a
sterile environment, four different conditions were pre-
pared each in the concentration of 10.000 PBMCs/μl in
FACS tubes: i) with K562 cells in 5:1 effector:target cell
ratio; ii) with phorbol-12-myristate-13-acetate (PMA)
(20 ng/ml) (Sigma Aldrich) and ionomycin (1 μg/ml)
(Sigma Aldrich); iii) with interleukin (IL)-12 (50 μg/ml)
and IL-18 (50 μg/ml); and iv) unstimulated control with
medium without additional additives. To all four condi-
tions, CD107a FITC (2 μg/ml) (BD Pharmingen, BD Bio-
sciences) and monensin (0,7 μg/ml) (BD GolgiStop, BD
Biosciences) were added. Cells were then incubated at
37 °C in 5 % CO2. After 1 h of incubation Brefeldin A
(BFA) (10 μg/ml) (Sigma Aldrich) was added to each
tube and incubation continued for yet another 5 h at
37 °C in 0,5 % CO2. Brefeldin A was added to prevent
spontaneous exocytosis of cytokine-containing vesicles
to enable intracellular staining, whilst monensin was
added to prevent the acidification of the cytokines inside
the vesicles and any subsequent degradation of CD107a
when internalized. After 6 h of stimulation, PBMCs were
labelled for NK cell marker expression CD3 PerCP cy5.5
(Biolegend), CD56 APC (BD biosciences) and a fixable
yellow dead cell marker (Invitrogen) for 20 min. Cells
were then fixed and permeabilized according to manu-
facturers instructions (BD Biosciences) and stained for
IFN-γ PE cy7 (BD Pharmingen, BD Biosciences) and
TNF-α efluor 450 (ebioscience) for 30 min. Cells were
then resuspended in PBS/BSA and measured using
fluorescence-activated cell sorting (FACS) Canto (BD
Bisciences) in the FACS facility of the DRFZ and ac-
quired with DivaSoftware. A total of 20,000 to 50,000
NK cells per tube were recorded. Analysis was made
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using FlowJo software version 8.7 for Mac. The gating
was performed as follows: gating on lymphocyte
population, exclusion of dead cells, and selection of
CD3− CD56+ cells. After adequately compensated, the
expression of CD107a+, IFN-γ+, TNF-α+ was individu-
ally measured [40].
Observation period
The first observational time point was chosen with
respect to the expected time when the quantitative
immune depression recedes according to the SCI-IDS
pilot study [6]. Three time windows were elected for
blood sampling and subsequent analysis to provide
insight about late acute, postacute and sub-acute
phases post-trauma: day 5 to 9 (mentioned as week
1) day 11 to 28 (mentioned as week 2) and 8th to
12th week (mentioned as week 10) after the injury
(Fig. 2). These were selected because they corre-
sponded to the hallmarks of parenchymal inflamma-
tion following SCI and were in line with previous
trials where immunological changes had also been ob-
served [36].
Primary and secondary endpoints
The primary endpoint is to analyse NK cytotoxicity
during the sub-acute phase (8–12 weeks) after SCI. NK
cells cytotoxic capacity was measured by quantifying the
expression of CD107a, a molecule expressed by exocyt-
osis of the cytotoxic granules.
NK cell 107a expression can be elicited by two
ways: 1) Exposure of NK cells to specific target cells
– K562, an erythroleukemic cell line devoid of MHC
I [24, 25, 40, 41]; 2) PMA and ionomycin stimulation
[40]. PMA is a robust lymphocyte activation stimulus
bypassing membrane receptors acting through protein
kinase C activation pathway and ionomycin is a calcium
ionophore [24, 40].
Secondary endpoints of the study are the quantifica-
tion of the NK cell’s IFN-γ and TNF-α production dur-
ing the subacute phase. IFN-γ and TNF-α production
can be triggered through a well-established immuno-
logical challenge: PMA and ionomycin stimulation [22].
The released IFN-γ and TNF-α synthesis denotes the in-
trinsic potential of each NK cell to produce cytokines.
The frequency of degranulating and cytokine-producing
NK cells was measured by multicolour flow cytometry.
Data and statistical analysis
Administrative intermediate feasibility evaluations were
performed during the enrolment period to assure appro-
priateness of the recruitment schedule.
Data analysis of the primary endpoint consists of a two
group comparison between all SCI-patients (groups i and
ii) and the control group of patients with acute vertebral
fracture (group iii). Furthermore, in secondary analyses we
plan the comparison between the 3 separate patient
groups (i-iii) and the reference group of healthy controls
(group iv) over the 3 consecutive time intervals using ad-
justed linear mixed models as implemented in the soft-
ware package SPSS (IBM Corp. Released 2013. IBM SPSS
Statistics for Windows, Version 22.0. Armonk, NY: IBM
Corp.). The analysis was performed using the full dataset
comprising all patients included according to the criteria
as defined in the study protocol.
Outcomes
The aim is to identify functional NK cells impairment as a
component of lymphocyte-mediated non-specific immun-
ity at different stages after injury with a more in depth
consideration from different stages after SCI. The purpose
is to better characterize SCI-IDS, establish potential prog-
nostic criteria in patients at highest risk for SCI-associated
infections, and possibly suggest novel preventive thera-
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Time window
Precise timing
Fig. 2 Scheduled patient’s visits. Blood collection, patient documentation and NK cell assays was performed during indicated time-windows. The
timeline is starting at the time of injury (SCI)
Laginha et al. BMC Neurology  (2016) 16:170 Page 6 of 8
Furthermore, in order to challenge the hypothesis of a
neurogenic origin of NK dysfunction we also aim to
establish a correlation between the lesion level and
severity with the extent of NK dysfunction. Ultimately
the results from this study might influence guidelines
regarding early recognition of the SCI-IDS and diagnosis
of subsequent infections leading to targeted immune
and antibiotic therapies in order to enhance functional
neurological recovery in SCI patients.
Discussion
This prospective study investigates the influence of SCI
on NK cell activity taking into account its progression
through established disease phases as well as a depend-
ency on lesion level and the sympathetic innervation of
immune relevant organs. The aim is to characterize SCI-
IDS in qualitative terms beyond the first week following
injury, investigating not only cell counts but also cellular
function [5–7]. We hypothesize that disruption of spinal
cord sympathetic outflow causes a pronounced pro-
tracted immune deficiency by targeting NK cell function
and extending throughout the acute, post-acute and sub-
acute phases following SCI. Furthermore, we
hypothesize that patients with a Th5 lesion or higher, lo-
cated above the sympathetic outlet of the immune rele-
vant organs conveyed by the celiac and subsequent
paravertebral ganglia, have a lower residual NK cells
function than patients with a lesion at Th6 or lower,
where the sympathetic preganglionic neurons are par-
tially or completely intact. Moreover, we hypothesize
that NK cells of patients with a vertebral fracture (con-
trols) without any neurological deficit perform better
than those in the other two groups. In contrast to previ-
ous studies and by using FACS, we address the question
whether additional NK cell functions beyond cytotox-
icity, such as cytokine production were compromised by
SCI during the study period.
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